Skip to Content

Galvus Approval Status

Galvus (vildagliptin) is a dipeptidyl peptidase 4 (DPP-4) inhibitor intended for use as a once-daily oral treatment for patients with type 2 diabetes.

In February 2007, Novartis Pharmaceuticals Corporation announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) requesting additional data, including a clinical study to demonstrate the safety and efficacy of Galvus (vildagliptin) in specific patient groups with renal impairment. While vildagliptin is currently available in many countries, it remains commercially undeveloped in the United States.

Development Status and FDA Approval Process for Galvus

Feb 26, 2007Novartis Committed to Making Galvus Available for Patients with Type 2 Diabetes After US Regulators Issue ''Approvable Letter''
Nov 13, 2006Novartis announces three-month extension of US regulatory review for Galvus to assess recently available clinical data
Mar 30, 2006New drug application for Galvus, an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.